

# ADVANCED COURSE PROGRAMME

## KRAS Targeting in NSCLC

**ESMO VIRTUAL  
ADVANCED COURSE**

**ONLINE  
28-29 NOVEMBER 2022**

**Chairs**

Myung-Ju Ahn, Korea

Federica Di Nicolantonio, Italy

# ESMO VIRTUAL ADVANCED COURSE PROGRAMME

## KRAS targeting in NSCLC

28-29 November 2022

---

**CO-CHAIRS** Myung-Ju Ahn, Republic of Korea  
Federica Di Nicolantonio, Italy

**SPEAKERS** Mariano Barbacid, Spain  
Keith M. Kerr, United Kingdom  
Hye Ryun Kim, Republic of Korea  
Se-Hoon Lee, Republic of Korea  
Ziming Li, China  
Laura Mezquita, Spain  
Misako Nagasaka, United States  
Takashi Seto, Japan  
Ferdinandos Skoulidis, United States  
Daniel S. W. Tan, Singapore

---

### LEARNING OBJECTIVES

- To understand the function and biology of KRAS in normal and malignant cells
- To gain insights in the spectrum of KRAS molecular aberrations, platforms and strategies for molecular testing
- To discuss emerging therapeutic strategies and clinical research in KRAS mutated NSCLC
- To present novel data on biomarkers of benefit, mechanisms of resistance and combinatorial therapeutic strategies of KRAS G12C inhibition and beyond

---

### ACCREDITATION

The programme of this event has been accredited with **6 ESMO-MORA category 1 points**. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further information please refer to [www.esmo.org](http://www.esmo.org).

---

### ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



---

### ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4  
6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



**All timings are to be considered GMT+8 (Singapore Local Time)**

**Monday, 28 November 2022**

---

- 15:00-15:10     **Welcome and introduction**  
10'             Myung-Ju Ahn, KR
- 15:10-16:45     **Session 1 – KRAS Biology, Epidemiology, Pathology**  
Chair: Federica Di Nicolantonio, IT
- 20'             The structure, function and role of KRAS in normal cell homeostasis  
Mariano Barbacid, ES
- 20'             Epidemiology of KRAS activating mutations: Incidence and biology across tumours with emphasis on lung cancer  
Takashi Seto, JP
- 20'             Molecular landscape of KRAS mutant NSCLC (molecular concomitant genetic alterations in KRAS mutant tumours)  
Se-Hoon Lee, KR
- 20'             Pathology and molecular testing of NSCLC for KRAS mutations: Who, how and when? (tissue, liquid biopsy)  
Keith M. Kerr, UK
- 15'             Discussion
- 16:45-17:00     *Break*
- 17:00-18:35     **Session 2 – Targeting KRAS G12C in Lung Cancer**  
Chair: Myung-Ju Ahn, KR
- 20'             Clinical development of KRAS G12C inhibitors: Where are we now?  
Ziming Li, CN
- 20'             Resistance to KRAS G12C inhibitors: What do we know?  
Daniel S. W. Tan, SG
- 20'             Moving forward with KRAS G12C inhibitors : Combinations (only chemotherapy and targeted therapy sequencing)  
Ferdinandos Skoulidis, US
- 15'             Discussion
- 20'             Clinical cases and Expert Panel Discussion
- 10' with discussion – Combination therapy, Daniel S. W. Tan, SG
- 10' with discussion – Single agent case with liver toxicity, Ziming Li, CN

## Tuesday, 29 November 2022

---

### 15:00-16:15 **Session 3 – Moving beyond KRAS G12C**

Chair: Federica Di Nicolantonio, IT

- 20' Targeting KRAS beyond G12C: What is coming?  
Hye Ryun Kim, KR
- 20' Targeting KRAS with checkpoint inhibitors  
Laura Mezquita, ES
- 20' Vaccine and adoptive cell therapy strategies for the treatment of KRAS mutant NSCLC  
Misako Nagasaka, US
- 15' Discussion

16:15-16:30 *Break*

### 16:30-18:00 **Workshop Sessions**

- 10' Introduction based on clinical cases presented by speakers
- 20' Discussion

#### **Workshop 1** Liquid biopsy applications for RAS-mutated mutational profiling, monitoring of disease course, clonal evolution and resistance in NSCLC

- 30' Laura Mezquita, ES  
Keith M. Kerr, UK

#### **Workshop 2** Moving forward with KRAS G12C inhibitors in early stage/locally advanced NSCLC

- 30' Ziming Li, CN  
Daniel S. W. Tan, SG

#### **Workshop 3** Designing practice-changing trials: Key considerations

- 30' Myung-Ju Ahn, KR  
Federica Di Nicolantonio, IT

### 18:00-18:15 **Synthesis and wrap-up**

Myung-Ju Ahn, KR  
Federica Di Nicolantonio, IT